Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | LPL | P06858 | 3/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1841675 | 1.00 | POLB (0.37) | POLBSMN1; SMN2FFAR1TSHRMEN1 | |
| SCHEMBL2188747 | 0.98 | FFAR1 (0.37) | POLBSMN1; SMN2FFAR1TSHRMEN1 | |
| SCHEMBL23797377 | 0.95 | FFAR1 (0.37) | POLBSMN1; SMN2FFAR1TSHRLPL | |
| SCHEMBL3617694 | 0.87 | POLB (0.42) | POLBSMN1; SMN2TSHRKMT2AALDH1A1 | |
| SCHEMBL1877437 | 0.86 | POLB (0.46) | POLBSMN1; SMN2FFAR1TSHRKMT2A | |
| SCHEMBL1484840 | 0.86 | HTR3A (0.41) | FFAR1TSHRKMT2ALPLLIPG | |
| SCHEMBL15416326 | 0.84 | ALDH1A1 (0.45) | SMN1; SMN2FFAR1TSHRALDH1A1DGAT1 | |
| SCHEMBL25302891 | 0.84 | FFAR1 (0.35) | FFAR1LPLLIPGDGAT1USP30 | |
| SCHEMBL19818266 | 0.84 | FFAR1 (0.33) | POLBFFAR1TSHRLPLLIPG | |
| SCHEMBL24894860 | 0.83 | USP30 (0.35) | POLBFFAR1LPLLIPGMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105664-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | disclosed |
| US-20100105664-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | disclosed |
| WO-2008034600-A1 | PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES | NOVARTIS AG (CH) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105664-A1 | ORGANIC COMPOUNDS | SLCO1B3, SLCO1B1, SLC10A6 | POLB 2919/4885SMN1; SMN2 1664/4885FFAR1 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.